


10 November 2025

FOR PUBLIC RELEASE

Rua Bioscience sets new quarterly revenue record, underscoring growth

Rua Bioscience is pleased to announce a record revenue result for Q1 FY26 ending September 2025, marking a milestone in the company's commercial growth. This achievement reflects Rua's ability to deliver strong sales outcomes across all key markets, including New Zealand, Australia, and Germany.

Customer revenue



The company's best-ever sales performance highlights both growing demand for Rua's medicinal cannabis products and the effectiveness of its export-led commercial strategy. It also demonstrates Rua's ability to scale sales rapidly, provided appropriate funding is in place to support supply and expansion.

Chief Executive Officer Paul Naske said, "This quarter's results reaffirm that Rua can grow sales effectively across markets. With continued access to funding, we are confident in our ability to maintain this trajectory and expand further."

Rua's commercial progress aligns with its founding purpose: to create a high-value, intergenerational company that delivers quality New Zealand-grown medicinal cannabis products to patients at home and abroad. With channels now active in four international markets and a growing product portfolio, Rua is positioned to grow further.

ENDS

The person who authorised this statement:

Paul Naske

Chief Executive Officer

paul.naske@ruabio.com

+64 21 445154